RSLS icon

ReShape Lifesciences

2.53 USD
+0.20
8.58%
At close Jul 30, 4:00 PM EDT
After hours
2.47
-0.06
2.37%
1 day
8.58%
5 days
-25.15%
1 month
3.69%
3 months
-70.09%
6 months
-97.32%
Year to date
-97.78%
1 year
-99.13%
5 years
-100.00%
10 years
-100.00%
 

About: Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.

Employees: 18

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

30% more funds holding

Funds holding: 10 [Q4 2024] → 13 (+3) [Q1 2025]

0.44% more ownership

Funds ownership: 2.69% [Q4 2024] → 3.13% (+0.44%) [Q1 2025]

56% less capital invested

Capital invested by funds: $85.3K [Q4 2024] → $37.4K (-$47.9K) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for RSLS.

Financial journalist opinion

Based on 4 articles about RSLS published over the past 30 days

Neutral
GlobeNewsWire
6 days ago
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
Neutral
GlobeNewsWire
1 week ago
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
Neutral
GlobeNewsWire
1 week ago
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Neutral
GlobeNewsWire
4 weeks ago
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq's stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed.
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic headcount reduction and provided an update on the merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad Medisys.
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
Recon Supply Named Exclusive U.S. Distributor of ReShape's STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service Members Recon Supply Named Exclusive U.S. Distributor of ReShape's STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service Members
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ®  (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share.
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively.
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
Charts implemented using Lightweight Charts™